Reference

·

Supporting source

Korean Implant Brand ASP Versus Straumann/Nobel Biocare

~40-50% of premium brand ASP

As ofFY2024-2027E·Sources3·Supporting

Korean implant brands (Osstem, Dentium, Megagen) distribute in Thailand at approximately 40-50% of Straumann and Nobel Biocare average selling price. The pricing spread is the main lever compressing premium-clinic gross margin on implant body from approximately 62% to 55% as Korean unit share rises toward 35-40% of Thai implant volume by 2027.

Figure in context

Korean implant brands (Osstem, Dentium, Megagen) distribute in Thailand at approximately 40-50% of Straumann and Nobel Biocare average selling price. The pricing spread is the main lever compressing premium-clinic gross margin on implant body from approximately 62% to 55% as Korean unit share rises toward 35-40% of Thai implant volume by 2027.

Korean implant brands (Osstem, Dentium, Megagen) distribute in Thailand at approximately 40-50% of Straumann and Nobel Biocare average selling price. The pricing spread is the main lever compressing premium-clinic gross margin on implant body from approximately 62% to 55% as Korean unit share rises toward 35-40% of Thai implant volume by 2027.

Time scope

FY2024-2027E

Source basis

Supporting source

Interpretation notes

What this tells you

Korean implant brands (Osstem, Dentium, Megagen) distribute in Thailand at approximately 40-50% of Straumann and Nobel Biocare average selling price. The pricing spread is the main lever compressing premium-clinic gross margin on implant body from approximately 62% to 55% as Korean unit share rises toward 35-40% of Thai implant volume by 2027.

What not to do with it

Use the linked report for interpretation and keep basis differences explicit.

Related figures

Adjacent numbers that add context without drowning the value.

Report context

Atlas actors in this figure's reports

Profiles covered in the report that cite this number.

Korean Implant Brand ASP Versus Straumann/Nobel Biocare · Insight